OBJECTIVE: The Global Fund to Fight AIDS, Tuberculosis and Malaria is one of the largest funders to fight these diseases. This paper discusses the programmatic contribution of Global Fund-supported programmes towards achieving international targets and Millennium Development Goals, using data from Global Fund grants. METHODOLOGY: Results until June 2006 of 333 grants supported by the Global Fund in 127 countries were aggregated and compared against international targets for HIV/AIDS, tuberculosis and malaria. Progress reports to the Global Fund secretariat were used as a basis to calculate results. Service delivery indicators for antiretrovirals (ARV) for HIV/AIDS, case detection under the DOTS strategy for tuberculosis (DOTS) and insecticide-treated nets (ITNs) for malaria prevention were selected to estimate programmatic contributions to international targets for the three diseases. Targets of Global Fund-supported programmes were projected based on proposals for Rounds 1 to 4 and compared to international targets for 2009. FINDINGS: Results for Global Fund-supported programmes total 544,000 people on ARV, 1.4 million on DOTS and 11.3 million for ITNs by June 2006. Global Fund-supported programmes contributed 18% of international ARV targets, 29% of DOTS targets and 9% of ITNs in sub-Saharan Africa by mid-2006. Existing Global Fund-supported programmes have agreed targets that are projected to account for 19% of the international target for ARV delivery expected for 2009, 28% of the international target for DOTS and 84% of ITN targets in sub-Saharan Africa. CONCLUSION: Global Fund-supported programmes have already contributed substantially to international targets by mid-2006, but there is a still significant gap. Considerably greater financial support is needed, particularly for HIV, in order to achieve international targets for 2009.
OBJECTIVE: The Global Fund to Fight AIDS, Tuberculosis and Malaria is one of the largest funders to fight these diseases. This paper discusses the programmatic contribution of Global Fund-supported programmes towards achieving international targets and Millennium Development Goals, using data from Global Fund grants. METHODOLOGY: Results until June 2006 of 333 grants supported by the Global Fund in 127 countries were aggregated and compared against international targets for HIV/AIDS, tuberculosis and malaria. Progress reports to the Global Fund secretariat were used as a basis to calculate results. Service delivery indicators for antiretrovirals (ARV) for HIV/AIDS, case detection under the DOTS strategy for tuberculosis (DOTS) and insecticide-treated nets (ITNs) for malaria prevention were selected to estimate programmatic contributions to international targets for the three diseases. Targets of Global Fund-supported programmes were projected based on proposals for Rounds 1 to 4 and compared to international targets for 2009. FINDINGS: Results for Global Fund-supported programmes total 544,000 people on ARV, 1.4 million on DOTS and 11.3 million for ITNs by June 2006. Global Fund-supported programmes contributed 18% of international ARV targets, 29% of DOTS targets and 9% of ITNs in sub-Saharan Africa by mid-2006. Existing Global Fund-supported programmes have agreed targets that are projected to account for 19% of the international target for ARV delivery expected for 2009, 28% of the international target for DOTS and 84% of ITN targets in sub-Saharan Africa. CONCLUSION: Global Fund-supported programmes have already contributed substantially to international targets by mid-2006, but there is a still significant gap. Considerably greater financial support is needed, particularly for HIV, in order to achieve international targets for 2009.
Authors: B Schwartländer; J Stover; N Walker; L Bollinger; J P Gutierrez; W McGreevey; M Opuni; S Forsythe; L Kumaranayake; C Watts; S Bertozzi Journal: Science Date: 2001-06-21 Impact factor: 47.728
Authors: John Stover; Neff Walker; Geoff P Garnett; Joshua A Salomon; Karen A Stanecki; Peter D Ghys; Nicholas C Grassly; Roy M Anderson; Bernhard Schwartländer Journal: Lancet Date: 2002-07-06 Impact factor: 79.321
Authors: J Ties Boerma; Karen A Stanecki; Marie-Louise Newell; Chewe Luo; Michel Beusenberg; Geoff P Garnett; Kirsty Little; Jesus Garcia Calleja; Siobhan Crowley; Jim Yong Kim; Elizabeth Zaniewski; Neff Walker; John Stover; Peter D Ghys Journal: Bull World Health Organ Date: 2006-02-23 Impact factor: 9.408
Authors: John Stover; Stefano Bertozzi; Juan-Pablo Gutierrez; Neff Walker; Karen A Stanecki; Robert Greener; Eleanor Gouws; Catherine Hankins; Geoff P Garnett; Joshua A Salomon; J Ties Boerma; Paul De Lay; Peter D Ghys Journal: Science Date: 2006-02-02 Impact factor: 47.728
Authors: Joshua A Salomon; Daniel R Hogan; John Stover; Karen A Stanecki; Neff Walker; Peter D Ghys; Bernhard Schwartländer Journal: PLoS Med Date: 2005-01-11 Impact factor: 11.069
Authors: Daniel Low-Beer; Houtan Afkhami; Ryuichi Komatsu; Prerna Banati; Musoke Sempala; Itamar Katz; John Cutler; Paul Schumacher; Ronald Tran-Ba-Huy; Bernhard Schwartländer Journal: PLoS Med Date: 2007-08 Impact factor: 11.069
Authors: Ryuichi Komatsu; Eline L Korenromp; Daniel Low-Beer; Catherine Watt; Christopher Dye; Richard W Steketee; Bernard L Nahlen; Rob Lyerla; Jesus M Garcia-Calleja; John Cutler; Bernhard Schwartländer Journal: BMC Infect Dis Date: 2010-04-30 Impact factor: 3.090
Authors: Immo Kleinschmidt; Christopher Schwabe; Murugasampilay Shiva; Jose Luis Segura; Victor Sima; Samuel Jose Alves Mabunda; Michael Coleman Journal: Am J Trop Med Hyg Date: 2009-09 Impact factor: 2.345
Authors: Ana P Abilio; Immo Kleinschmidt; Andrea M Rehman; Nelson Cuamba; Varsha Ramdeen; David S Mthembu; Sarel Coetzer; Rajendra Maharaj; Craig S Wilding; Andrew Steven; Marlize Coleman; Janet Hemingway; Michael Coleman Journal: Malar J Date: 2011-05-02 Impact factor: 2.979